obesity drug news today glp-1 2025 trends 2025: real-world data, patient outcomes & future therapies obesity drug news today glp-1

If you are starting a GLP-1 medication, following the prescribed semaglutide dosage schedule or tirzepatide dosing guide carefully matters

2024 Sep 10;2024 doi: 10.1155/2024/9960656

Another triple agonist (HM15211) is undergoing phase 1 clinical trials with no published data so far

* However, in the 1960s, interest in incretine was invigorated by the observation of three groups that orally delivered glucose increased circulating insulin concentrations and lowered blood glucose to a greater extent than did intravenously administered glucose (1)

THE CONCIERGE MEDICINE GUIDE Is Concierge Medicine Actually Right for You